Unilateral repetitive transcranial magnetic stimulation differentially affects younger and older adults completing a verbal working memory task

2018 ◽  
Vol 384 ◽  
pp. 15-20 ◽  
Author(s):  
Jessica Shields ◽  
Jeffrey Mock ◽  
Deidre Devier ◽  
Anne Foundas
2018 ◽  
Vol 15 (6) ◽  
pp. 570-577 ◽  
Author(s):  
Wenwen Bai ◽  
Tiaotiao Liu ◽  
Mengmeng Dou ◽  
Mi Xia ◽  
Jun Lu ◽  
...  

Background: Alzheimer's disease (AD) is a neurodegenerative disease that gradually induces cognitive deficits in the elderly and working memory impairment is typically observed in AD. Amyloid-β peptide (Aβ) is a causative factor for the cognitive impairments in AD. Gamma oscillations have been recognized to play important roles in various cognitive functions including working memory. Previous study reported that Aβ induces gamma oscillation dysfunction in working memory. Objective: Although repetitive transcranial magnetic stimulation (rTMS) represents a technique for noninvasive stimulation to induce cortical activity and excitability changes and has been accepted for increasing brain excitability and regulating cognitive behavior, the question whether rTMS can reserve the Aβ-induced gamma oscillation dysfunction during working memory remains unclear. The present study aims to investigate the effect of rTMS to the Aβ-induced gamma oscillation dysfunction during working memory. Method: The present study investigates the rTMS-modulated gamma oscillation in Aβ1-42-induced memory deficit. Adult SD rats were divided into four groups: Aβ, Con, Aβ+rTMS and Con+rTMS. 16-channel local field potentials (LFPs) were recorded from rat medial prefrontal cortex while the rats performed a Y-maze working memory task. Gamma oscillation among LFPs was measured by coherence. Results: The results show that rTMS improved the behavior performance and enhanced gamma oscillation for the Aβ-injected subjects. Conclusion: These results indicate that rTMS may reserve the Aβ-induced dysfunction in gamma oscillation during working memory and thus result in potential benefits for working memory.


2021 ◽  
Vol 12 ◽  
Author(s):  
Li-Jin Wang ◽  
Lin-Lin Mu ◽  
Zi-Xuan Ren ◽  
Hua-Jun Tang ◽  
Ya-Dong Wei ◽  
...  

Background: Repetitive transcranial magnetic stimulation (rTMS) has therapeutic effects on craving in methamphetamine (METH) use disorder (MUD). The chronic abuse of METH causes impairments in executive function, and improving executive function reduces relapse and improves treatment outcomes for drug use disorder. The purpose of this study was to determine whether executive function helped predict patients' responses to rTMS treatment.Methods: This study employed intermittent theta burst stimulation (iTBS) rTMS modalities and observed their therapeutic effects on executive function and craving in MUD patients. MUD patients from an isolated Drug Rehabilitation Institute in China were chosen and randomly allocated to the iTBS group and sham-stimulation group. All participants underwent the Behavior Rating Inventory of Executive Function - Adult Version Scale (BRIEF-A) and Visual Analog Scales (VAS) measurements. Sixty-five healthy adults matched to the general condition of MUD patients were also recruited as healthy controls.Findings: Patients with MUD had significantly worse executive function. iTBS groups had better treatment effects on the MUD group than the sham-stimulation group. Further Spearman rank correlation and stepwise multivariate regression analysis revealed that reduction rates of the total score of the BRIEF-A and subscale scores of the inhibition factor and working memory factor in the iTBS group positively correlated with improvements in craving. ROC curve analysis showed that working memory (AUC = 87.4%; 95% CI = 0.220, 0.631) and GEC (AUC = 0.761%; 95% CI = 0.209, 0.659) had predictive power to iTBS therapeutic efficacy. The cutoff values are 13.393 and 59.804, respectively.Conclusions: The iTBS rTMS had a better therapeutic effect on the executive function of patients with MUD, and the improved executive function had the potential to become a predictor for the efficacy of iTBS modality for MUD treatment.Clinical Trial Registration:ClinicalTrials.gov, identifier: ChiCTR2100046954.


2013 ◽  
Vol 6 (6) ◽  
pp. 905-912 ◽  
Author(s):  
Anne Weigand ◽  
Aline Richtermeier ◽  
Melanie Feeser ◽  
Jia Shen Guo ◽  
Benny B. Briesemeister ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document